The effect of ZD1839 (IressaTM), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells-Reference-Cited by-同舟云学术

The effect of ZD1839 (IressaTM), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells

Published:2005-04 Issue:2 Volume:38 Page:77-86
ISSN:0960-7722
Container-title:Cell Proliferation
language:en
Short-container-title:Cell Prolif

Author:

Al-Hazzaa A.,Bowen I. D.,Randerson P.,Birchall M. A.

Publisher

Wiley

Subject

Cell Biology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2184.2005.00332.x/fullpdf

Reference30 articles.

1. Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy

2. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

3. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obovatol inhibits the growth and aggressiveness of tongue squamous cell carcinoma through regulation of the EGF‑mediated JAK‑STAT signaling pathway;Molecular Medicine Reports;2018-05-25

2. Concurrent chemoradiation with weekly Cisplatin, Docetaxel and Gefitinib: A study to assess feasibility, toxicity and immediate response;Journal of Cancer Research and Therapeutics;2013

3. Phase II Prospective Trial of Gefitinib Given Concurrently with Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck Cancer;J OTOLARYNGOL-HEAD N;2010

4. Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future;Oncology Reviews;2009-08-28

5. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia;European Journal of Haematology;2008-07